# Evaluation of efficacy and safety of coenzyme Q10 in pediatric hemodialysis patients: a randomized controlled trial

## Access

| Field | Value |
|-------|-------|
| DOI | `10.1186/s43094-024-00752-9` |
| Full Paper | [https://doi.org/10.1186/s43094-024-00752-9](https://doi.org/10.1186/s43094-024-00752-9) |
| Source | [https://journalclub.io/episodes/evaluation-of-efficacy-and-safety-of-coenzyme-q10-in-pediatric-hemodialysis-patients-a-randomized-controlled-trial](https://journalclub.io/episodes/evaluation-of-efficacy-and-safety-of-coenzyme-q10-in-pediatric-hemodialysis-patients-a-randomized-controlled-trial) |
| Year | 2026 |
| Citations | 0 |
| Authors |  |
| Paper ID | `a62a8b15-2abb-4235-b641-d8df7976f665` |

## Classification

- **Problem Type:** biomedical intervention evaluation
- **Domain:** Bioinformatics & Health
- **Sub-domain:** Pediatric Nephrology
- **Technique:** Coenzyme Q10 supplementation
- **Technique Category:** therapeutic intervention
- **Type:** novel (new method)

## Summary

This study investigates the effects of coenzyme Q10 supplementation on oxidative stress and inflammatory markers in pediatric hemodialysis patients, demonstrating significant improvements in certain biomarkers. Engineers should care because this research provides insights into potential therapeutic interventions for vulnerable populations, which could lead to the development of new treatment protocols or medical devices.

## Key Contribution

**Demonstrated that coenzyme Q10 supplementation significantly reduces oxidative stress and inflammatory markers in pediatric hemodialysis patients.**

## Problem

The study addresses the high oxidative stress and inflammation levels in pediatric patients undergoing hemodialysis, which can lead to poor health outcomes.

## Method

**Approach:** The method involves a randomized controlled trial where pediatric hemodialysis patients receive either coenzyme Q10 or a placebo for 12 weeks. The primary outcomes are measured through changes in oxidative stress and inflammatory markers in the blood.

**Algorithm:**

1. 1. Recruit pediatric hemodialysis patients aged 2-18 years.
2. 2. Randomly assign participants to either coenzyme Q10 or placebo group.
3. 3. Administer daily doses of coenzyme Q10 (3-5 mg/kg) or placebo for 12 weeks.
4. 4. Collect blood samples before and after the intervention to measure biomarkers.
5. 5. Analyze the data using appropriate statistical methods to compare groups.

**Input:** Pediatric hemodialysis patients, blood samples for biomarker analysis.

**Output:** Changes in serum levels of malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), and other biomarkers.

**Key Parameters:**

- `coenzyme Q10 dosage: 3-5 mg/kg/day`
- `study duration: 12 weeks`

**Complexity:** not stated

## Benchmarks

**Tested on:** 36 pediatric hemodialysis patients

**Results:**

- MDA: median percent change -55.68 in intervention vs. 39.75 in placebo (p<0.001)
- TNF-α: median percent change -46.69 in intervention vs. 8.5 in placebo (p=0.03)
- BUN: reduction from 134 to 60.5 mg/dL in intervention (p=0.012)

**Compared against:** Placebo group results

**Improvement:** Significant reduction in oxidative stress markers compared to placebo.

## Implementation Guide

**Data Structures:** Patient records, Biomarker measurement logs

**Dependencies:** Clinical trial management software, Statistical analysis tools (e.g., SPSS)

**Core Operation:**

```python
if patient.group == 'intervention': administer_coenzyme_Q10() else: administer_placebo()
```

**Watch Out For:**

- Ensure proper randomization to avoid bias.
- Monitor patient compliance with capsule intake.
- Account for potential confounding factors in analysis.

## Use This When

- Developing treatment protocols for pediatric patients on hemodialysis.
- Investigating the effects of antioxidants in chronic conditions.
- Designing clinical trials for new therapeutic interventions.

## Don't Use When

- Addressing acute medical emergencies.
- Working with adult populations without prior pediatric data.
- When patients are contraindicated for antioxidant supplementation.

## Key Concepts

oxidative stress, inflammation, coenzyme Q10, pediatric hemodialysis, biomarkers, randomized controlled trial

## Connects To

- Antioxidant therapies
- Chronic kidney disease management
- Pediatric clinical trial methodologies

## Prerequisites

- Understanding of oxidative stress and its implications in health.
- Knowledge of pediatric nephrology and hemodialysis.
- Familiarity with clinical trial design and statistical analysis.

## Limitations

- Small sample size may limit generalizability.
- Short duration of the study may not capture long-term effects.
- Potential dropout rates affecting statistical power.

## Open Questions

- What are the long-term effects of coenzyme Q10 supplementation in pediatric populations?
- Can higher doses of coenzyme Q10 provide additional benefits without adverse effects?

## Abstract

Today we will look at hemodialysis (HD), and the impact that it has on the body. We will focus on the oxidative stress and inflammation experienced by HD patients and how this is currently being addressed. The authors of today's paper set up a randomized control trial to determine if the positive effects of coenzyme Q10 in adult HD patients would translate to the pediatric population. If your kidneys are functioning badly, and resources allow for it, you get HD. HD is a treatment for kidney failure that uses a machine, and a special filter called a dialyzer to clean your blood. It acts like an artificial kidney. So, how does this work? First, an arteriovenous fistula or graft would be surgically inserted into your arm. This implant of sorts is used to connect your bloodstream to the dialysis machine without puncturing your veins and arteries with large gauge needles every time you need HD. The machine connects to you with two
